Current Report Filing (8-k)
December 28 2020 - 8:35AM
Edgar (US Regulatory)
0001346830
false
0001346830
2020-12-28
2020-12-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 28, 2020
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-36279
|
75-3175693
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
4 Stamford
Plaza
107 Elm Street, 9th
Floor
Stamford, Connecticut
|
|
06902
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
Registrant's telephone number, including area code: (203) 406-3700
|
|
|
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2.):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share
|
CARA
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 7.01
|
Regulation FD Disclosure.
|
On December 28, 2020, Cara Therapeutics, Inc. (the
“Company”) issued a press release announcing the submission of the new drug application to the U.S. Food and Drug Administration
for KORSUVA™ Injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The information furnished
under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed
incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of
any general incorporation language in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CARA THERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Derek Chalmers, Ph.D., D.Sc.
|
|
|
Derek Chalmers, Ph.D., D.Sc.
|
|
|
President and Chief Executive Officer
|
|
|
|
Date: December 28, 2020
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024